Polyclonal Antibody Market to Surpass US$ 1,350.0 Million by 2027 - Coherent Market Insights

Global Polyclonal Antibody Market, by Type (Primary Antibody and Secondary Antibody), by Application (Academic Research and Commercial), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 987.7 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Rising incidence of cancer is expected to augment the market growth.

Rising incidence of cancer is expected to drive the polyclonal antibody market growth. For instance, according to an article published by the American Cancer Society, 2016, an estimated 16.8 million new cases of cancer are diagnosed every year in the U.S., with around 595,690 deaths occurring due to cancer. The number of people with cancer is expected to rise to 19 million by 2024.

Global Polyclonal Antibody Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus disease (COVID-19) has resulted in over 70.46 million infected individuals worldwide, as of December 13, 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of raw materials from one place to another.

Browse 40 Market Data Tables and 35 Figures spread through 202 Pages and in-depth TOC on “Polyclonal Antibody Market – by Type (Primary Antibody and Secondary Antibody), by Application (Academic Research and Commercial), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027”

To know the latest trends and insights prevalent in the global polyclonal antibody market, click the link below:

https://www.coherentmarketinsights.com/market-insight/polyclonal-antibody-market-4347

Key players in the market are focusing on inorganic strategies for development of polyclonal antibodies. For instance, in January 2018, Abcam plc, a manufacturer of life science research tools, signed an agreement with Roche Diagnostics, a healthcare subsidiary of F. Hoffmann-La Roche AG for the rights to the product portfolio of Spring Bioscience Corporation (Spring), acquired by Roche (2007). This product portfolio comprises of 500 additional products, predominantly other monoclonal and polyclonal antibodies.

Key Takeaways of the Global Polyclonal Antibody Market:

• The global polyclonal antibody market is expected to exhibit a CAGR of 5.2% during the forecast period owing to rising incidence of cancer globally. According to an article published by the Cancer Research UK in 2014, around 357,000 new cancer cases were diagnosed in the U.K., accounting for 980 diagnosed cases per day. Breast, prostate, lung, and bowel cancers together accounted for over 53% of the total cancers in the U.K.
• Among type, the secondary antibody segment held a dominant position in the global polyclonal antibody market in 2019 owing to better recognition of multiple epitopes on a primary antibody and are more sensitive towards antigens.
• Among application, the commercial segment held a dominant position in the polyclonal antibody market in 2019, owing to the rising demand for polyclonal antibodies in therapeutics by pharmaceutical and biotechnological companies.
• Key players operating in the global polyclonal antibody market are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB. and GeneTex, Inc. among others.